Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2010

View Archived Issues

MerLion Pharmaceuticals discloses novel antibacterial agents

Novel antiviral compounds disclosed by U.S. scientists

NeuroSearch claims new ligands of nicotinic acetylcholine and monoamine receptors

NeuroSearch discovers novel monoamine reuptake inhibitors

Novel NS5B inhibitors for treatment of HCV infections claimed by Italian scientists

Single- and repeat-dose studies encourage further evaluation of ACU-4429 in AMD

Favorable preclinical safety of bispecific MM-111 antibody for HER2-positive solid tumors disclosed

Promising preclinical safety profile of new tenofovir analogue CMX-157 disclosed

Novel HIV maturation inhibitor MPI-0461359 developed at Myriad Pharmaceuticals

Second-generation cholesterol absorption inhibitors discovered at Merck & Co.

RAMBO; a new oncolytic viral therapeutic approach with potent preclinical activity

Arrayit appoints DOCRO to facilitate FDA approval of OvaDx ovarian cancer test

Syngene to collaborate with Endo to develop anticancer molecules

Cumberland submits Acetadote sNDA for acute liver failure to FDA

GSK resubmits Avodart sNDA for prostate cancer to FDA

Cephalon receives complete response letter from FDA for Nuvigil

Pearl presents phase I data on PT-003 for chronic obstructive pulmonary disease

FDA accepts for review Savient's resubmitted Krystexxa BLA

Immunovaccine Technologies begins enrollment in phase I trial of DPX-0907 cancer vaccine

Trius reports phase I data on intravenously dosed antibacterial torezolid

Clinical Data reports results of phase I Stedivaze studies

MMRF grants awards to Intellikine and Tragara for multiple myeloma therapies

Ascent Therapeutics changes name to Anchor Therapeutics

Dicerna and Ipsen enter into exclusive research collaboration

Alcon completes acquisition of Durezol and Zyclorin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...